$138.3 K

Nuo Therapeutics Revenue Q2, 2018
Nuo Therapeutics Net income (Q2, 2018)-590.2 K
Nuo Therapeutics EBIT (Q2, 2018)-582.7 K
Nuo Therapeutics Cash, 30-Jun-2018373.3 K

Nuo Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

11.6m7.8m11.5m472.4k721.0k

Revenue growth, %

(33%)48%(96%)

Cost of goods sold

8.4m6.6m

Gross profit

3.2m1.2m

Gross profit Margin, %

28%15%

Sales and marketing expense

6.2m893.1k712.7k

R&D expense

2.6m1.0m1.3m

General and administrative expense

6.8m6.0m9.0m3.3m3.8m

Operating expense total

21.2m6.0m44.9m5.2m15.2m

EBIT

(18.1m)(23.4m)(41.3m)(5.5m)(15.5m)

EBIT margin, %

(156%)(301%)(359%)(1155%)(2154%)

Interest expense

1.7m3.4m3.8m2.2k10.8k

Pre tax profit

(20.2m)(18.9m)(15.0m)

Income tax expense

18.6k19.6k(89.0k)

Net Income

(20.2m)(18.9m)(52.8m)(5.7m)(15.0m)

Nuo Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

3.3m15.9m922.3k2.6m693.5k

Inventories

1.1m2.3m254.4k70.0k35.6k

Current Assets

10.0m21.9m3.0m3.4m1.2m

PP&E

919.5k925.2k1.1m486.1k223.6k

Goodwill

1.1m1.1m2.1m

Total Assets

46.3m56.2m7.1m14.1m1.4m

Accounts Payable

8.0m1.9m1.1m392.6k380.3k

Short-term debt

3.6m

Current Liabilities

10.6m8.5m42.2m1.4m936.8k

Long-term debt

3.6m

Total Debt

7.2m

Total Liabilities

19.4m43.1m1.6m941.2k

Common Stock

993.0

Preferred Stock

3.0

Additional Paid-in Capital

117.1m125.2m126.0m18.2m21.2m

Retained Earnings

(91.2m)(110.1m)(162.9m)(5.7m)(20.7m)

Total Equity

26.3m15.5m(36.6m)12.5m482.9k

Debt to Equity Ratio

0.3 x

Debt to Assets Ratio

0.2 x

Financial Leverage

1.8 x3.6 x-0.2 x1.1 x2.9 x

Nuo Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(20.2m)(18.9m)(52.8m)(5.7m)(15.0m)

Depreciation and Amortization

1.1m613.5k741.0k836.2k1.1m

Inventories

58.6k(1.1m)272.0k(21.6k)19.4k

Accounts Payable

5.2m(1.5m)(811.0k)(2.5m)(12.3k)

Cash From Operating Activities

(11.4m)(17.4m)(14.4m)(7.8m)(4.9m)

Cash From Investing Activities

1.4m(349.2k)(629.4k)100.0k55.4k

Cash From Financing Activities

10.7m30.4m2.9m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(15.4m)(5.6m)(17.0m)(21.7m)4.1m3.2m(10.6m)(4.9m)(1.3m)(1.9m)(1.7m)(1.4m)(670.2k)(1.3m)

Depreciation and Amortization

875.1k217.7k438.6k481.1k345.7k532.7k208.6k310.0k26.1k51.8k

Inventories

(631.8k)380.0k519.9k566.8k(173.7k)(60.4k)95.8k4.3k367.5k(2.6k)(2.8k)

Accounts Payable

2.4m(78.1k)(689.4k)(1.7m)2.0m(139.6k)632.2k926.3k1.3m498.3k(14.3k)434.5k156.0k143.2k

Cash From Operating Activities

(8.1m)(3.9m)(8.8m)(13.6m)(8.9m)(11.7m)(2.6m)(1.3m)(546.6k)(822.2k)

Cash From Investing Activities

1.5m(75.7k)(42.4k)(75.7k)(140.4k)(241.3k)(13.0)2.0k

Long-term Borrowings

(6.2m)(6.2m)

Cash From Financing Activities

8.6m8.4m30.5m30.4m2.3m500.0k

Nuo Therapeutics Ratios

USDY, 2018

Financial Leverage

-3 x
Report incorrect company information

Nuo Therapeutics Employee Rating

1.72 votes
Culture & Values
3.0
Work/Life Balance
3.0
Senior Management
3.0
Salary & Benefits
3.0
Career Opportunities
3.0
Source